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ABSTRACT 
 Lymphadenectomy of lymph node metastasis (LNM) from hepatocellular 
carcinoma (HCC) may potentially improve survival of patients with intrahepatic 
tumors controllable by means of locolegional treatment. However, the treatment 
strategy has not gained wide clinical acceptance, especially in patients with multiple 
advanced HCC. Thus, the purpose of this study is to evaluate the role of 
lymphadenectomy combined with locoregional treatment for the management of 
multiple advanced HCC with LNM. 
 Between January 1998 and August 2012, 15 patients underwent a selective 
lymphadenectomy either concurrently or sequentially after hepatectomy. Seven of 15 
patients underwent reductive hepatectomy while the remaining 8 patients had 
hepatectomy at curative intent. In patients with reductive hepatectomy, 
lymphadenectomy was concurrently performed and the residual intrahepatic tumors 
were treated thereafter with additional locoregional treatments consisting of 
transcatheter arterial chemoembolization, radiofrequency ablation, and percutaneous 
isolated hepatic perfusion.  
 Only 4 patients (26.6%) of 15 patients developed lymph node recurrence. However, 
intrahepateic recurrence was encountered in 13 of 15 patients. The median survival 
time after lymphadenectomy was 25.2 months with the overall survival rates at 1, 2, 
and 3 years being 76.9%, 52.7%, and 26.4%, respectively. Selective lymphadenectomy 
and multimodal locoregional treatment in patients with multiple residual tumors 
exhibited a similar overall survival to complete resection of LNM and intrahepatic 
tumors (P=0.78). 
 Lymphadenectomy combined with an additional aggressive locoregional 
treatments may be justified in selected patients with multiple advanced HCC with 
LNM 
 
ABBREVIATION 
HCC, hepatocellular carcinoma; LNM, lymph node metastases; 
RFA, radiofrequency ablation; TACE, transcatheter arterial chemoembolization;  
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PIHP, percutaneous isolated hepatic perfusion; AFP, alpha-fetoprotein;  
PIVKA II, protein induced by vitamin K absence or antagonist-II. 
 
INTRODUCTION 
Lymph node metastasis (LNM) is not common in patients with hepatocellular carcinoma 
(HCC) as compared to other malignant diseases(1, 8), for which regional lymph node 
dissection is routinely practiced as an essential part of radical surgery(6, 15, 22). According 
to the Report of the 17th Nationwide Follow-up Survey of Primary Liver Cancer in Japan, 
the incidence of LNM in patients treated with hepatectomy was approximately 1.2% based 
on preoperative diagnostic imaging studies, and only 0.9% in histology(8). This could be 
explained by the fact that patients with HCC and LNM frequently have multiple intrahepatic 
tumors which generally preclude surgical intervention(2, 12, 25, 27). Several groups have 
described a slightly higher incidence of LNM from HCC ranging from 5.1% to 7.5% based 
on prophylactic lymph node dissection concurrently performed during hepatectomy(5, 23, 
30). These studies have agreed that LNM was uniformly a poor prognostic factor, and 
prophylactic lymphadenectomy does not contribute to overall survival (OS) of patients with 
HCC.  
The Liver Cancer Study Group of Japan has been concluding nationwide surveys of 
patients with HCC. But the data concerning HCC patients with histologically proven LNM 
has not been accumulated. Meanwhile, some paper reported that the median survival time 
(MST) of patients with LNM from HCC was limited approximately 6 months in the natural 
history(23). The MST with systemic chemotherapy for patients with LNM ranged from 5.6 
to 10.7 months, and those with radiation therapy were in the range of 7 to 14.7 months(13, 14, 
16, 17, 21, 29, 31, 33, 34). Therefore, Sorafenib (Nexavar; Bayer HealthCare 
Pharmaceuticals, Basel, Switzerland / Onyx Pharmaceuticals, Emeryville, CA) is currently 
the only recommended therapeutic option for advanced HCC with LNM in the European 
Guideline(3). Although advanced HCC with LNM generally preclude surgical treatments, 
lymphadenectomy of LNM has been advocated to date by several investigators(7, 9, 19, 24, 
26, 28). The candidates to surgical resection in these studies were strictly limited for those 
with metachronous, solitary LNM without intrahepatic tumors or with intrahepatic tumors 
potentially controllable by the standard therapeutic options. Thus, the role of 
lymphadenectomy of LNM remains unknown in the majority of patients with LNM. 
We have shown that percutaneous isolated hepatic perfusion (PIHP) is a potent 
locoregional treatment for patients with multiple intrahepatic tumors(10). In addition, 
reductive hepatectomy followed by PIHP produced a strong antitumoral effect on multiple 
advanced HCC, when liver function allows this concentrated treatment approach(11). Taken 
together, we have introduced an aggressive multimodal treatment strategy combining PIHP 
for multiple advanced HCC and surgical resection of LNM. 
The aim of this study is to report a pilot study on lymphadenectomy combined with 
aggressive locoregional treatments as represented by reductive hepatectomy followed by 
PIHP in patients with multiple advanced HCC and LNM 
 
MATERIALS AND METHODS 
Patients 
Between January 1998 and August 2012, 598 patients with HCC underwent surgical 
treatment at our institution. Among them, all patients with resectable LNM were listed to our 
trial. Resectable LNM were considered as follows; (1) isolated LNM; (2) solitary or a few 
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number of LNM; (3) no distant matastasis except lymph nodes (4) sufficient liver function 
for surgical operation; (5) metachronous LNM or synchronous LNM with controllable 
intrahepateic tumors. It is particularly worth noting that extensive intrahepatic tumors such as 
multinodular and bilobar distribution were not contraindication in our strategy. If the 
distribution and extent of the intrahepatic tumors did not allow complete surgical removal, 
we selected lymphadenectomy on a priority basis and reductive hepatectomy was added at 
the first stage. The residual intrahepatic tumors were treated subsequently at the second stage 
with additional locoregional treatments consisting of percutaneous radiofrequency ablation 
(RFA), transcatheter arterial chemoembolization (TACE), and PIHP in an optimal 
combination. We set a base date at the point of first diagnosis of HCC and defined 
synchronous / metachronous LNM. A typical case of two-stage treatment is shown in Fig.1. 
Six of 15 patients had synchronous LNM, while other 9 patients had metachronous LNM. 
All patients were followed every three months until death or until 2012 December. All 
fifteen patients were divided to 2 groups (group A/B) by presence or absence of residual 
intrahepatic tumors after lymphadencetomy. Patients belonging to group A underwent a 
two-stage procedure. In the group B, complete surgical clearance of LNM and intrahepatic 
tumors were simultaneously done. In term of host, tumor and LNM factors, characteristic of 
patients in group A and B were compared. And the therapeutic result of group A and B were 
also compared. 
 
Figure 1. 
The arterial phase images of abdominal dynamic contrast enhanced computed tomography 
(CT) of typical case of two-stage procedure for advanced HCC with LNM. 
A) Before first treatment (hepatectomy and lymphoadenectomy), bilobar multiple intrahepatic 
HCC (arrows) and LNM in the pancreatic head area (arrow head) were detected as positive 
enhancement area. An extended right lobectomy was required for complete clearance of 
intrahepatic lesion. B) After second operation, postoperative change for partial hepatectomy 
(arrow) and lymphadencetomy (arrow head). C) After perctenous isolated hepatic perfusion 
(PIHP) as a locolegional treatment, residual intrahepatic lesions changed to low density areas 
indicating tumor necrosis.
Surgical procedure of lymphadenectomy 
Surgical treatment for LNM was selective lymphadenectomy. A prophylactic lymph node 
dissection was not performed. The preoperative clinical diagnosis of LNM was based on the 
following findings from contrast-enhanced CT studies; (1) the short axis diameter of lymph 
node was minimally 10mm; (2) the lymph node showed hypervascularity in the 
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contrast-enhancement; (3) the size of lymph node became enlarged between following 
studies. 
Statistical analysis 
All data were analyzed using the statistical software JMP ver10 (SAS institute, cary, NC). 
The overall survival (OS) time was calculated from the date of lymphadenectomy. The mean 
value is shown as mean ± SE. The survival rates were calculated according to the 
Kaplan-Meier method. Differences in the survival curves were compared with log-rank 
statistics. P value less than 0.05 was considered as a statistically significant. 
 
RESULTS 
Table I lists the clinical characteristics of 15 patients with LNM. Twenty-seven nodes 
were pathologically proven as LNM from HCC. Hepatitis C virus was detected in 6 patients 
(40.0%) and 8 patients (53.3%) had cirrhotic liver. Among tumor factors, 10 patients 
(66.7%) had multiple HCCs. The vascular invasion was demonstrated in 9 patients (60.0%) 
in preoperative examination. The pathological features of HCC in 8 patients (53.3%) were 
Table I. Demographics of 15 patients 
Variable   Total Group A Group B p 
Host factor      
Age (year) mean 63.1 ± 2.2 65.5 ± 2.3 60.3 ± 3.8 0.45 
Sex male/female 13/2 8/0 5/2 0.65 
Viral hepatitis  none/HBs Ag/HCV Ab 6/3/6 2/2/4 4/1/2 0.44 
Liver status NL/CH/LC 3/4/8 1/3/4 2/1/4 0.57 
Tumor factor      
Number of  nodule single/multiple 5/10 1/7 4/3 0.06 
Maximum diameter (cm) mean ± SE 5.3 ± 0.7 5.1 5.6 0.62 
Gross classification † SN/others 8/7 5/3 3/4 0.44 
Vascular invasion present/absent 9/6 4/4 5/2 0.39 
TNM classification † T2/T3/T4 5/4/6 2/3/3 3/1/3 0.55 
Tumor cell differentiation † mode/poor 7/8 5/3 2/5 0.18 
Serum AFP (ng/ml) > 10 / <10 12/3 6/2 6/1 0.6 
Serum PIVKA II (mAU/ml) > 40 / <40 11/4 6/2 5/2 0.87 
LNM factor      
Time of appearance synchronous/metachronous 6/9 4/4 2/5 0.39 
Number per person mean ± SE 1.8 ± 0.4 1.8 ± 0.5 2.0 ± 0.5 0.58 
Diameter (cm) mean ± SE 3.6 ± 1.8 3.5 ± 1.9 3.8 ± 1.5 0.32 
Site Hepatoduodenal ligament 8 (29.6%) 6 2  
 Common hepatic artery 8 (29.6%) 3 5  
 Retropancreatic head 5 (18.5%) 4 1  
 Para-aortic area 2 (7.4%) 0 2  
 Celiac axis 2 (7.4%) 1 1  
 Root of the mesentery 1 (3.7%) 1 0  
  Cervical area 1 (3.7%) 0 1   
Group A; With Residual Intrahepatic tumors after lymphadenectomy  
Group B; Complete resection of both LNM and intrahepatic tumors    
HCV, hepatitis C virus;  HBV, hepatitis B virus; mode, moderately differentiated;  poor, poorly differentiated; 
AFP, alfa-feto protein; PIVKA II, protein induced by vitamin K absence or antagonist-II; SN, simple nodular type;  
† According to The General Rules for the Clinical and Pathological Study of Primary Liver Cancer, The 5th Edition, Revised 
Version from Liver Cancer Study Group of Japan.41 And one patient had no pathological data for intrahepatic tumor. 
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either poorly differentiated type or undifferentiated type. The mean number of LNM was 1.8 
± 0.4, and the mean diameter was 3.6 ± 1.8 cm. Most common site of LNM was in the 
hepatoduodenal ligament and along the common hepatic artery (29.6%), followed by the 
posterior surface of pancreatic head area (18.5%). Six patients (40.0%) had synchronous 
LNM. In 9 patients with metachronous LNM, the mean time to detection of LNM after initial 
treatment for primary HCC was 13.7 ± 3.2 months. There is no significant difference 
between characteristic of patients in group A and B in term of host, tumor, and LNM factors. 
Treatment courses of two groups were shown in Table II. There were no severe 
complications of lymphadenectomy. Five of 7 patients (71.4%) of Group B at initial 
presentation had eventually developed intrahepatic recurrence. Four patients (26.6%) of 15 
patients developed lymph node recurrence. Patient No.12 had lymph node recurrence and 
died after the surgery that was performed for the cervical lymph node recurrence with 
superior vena cava tumor thrombosis. Patient No.13 died with gastric hemorrhage due to 
LNM invading to the stomach. 
As of this writing, 6 of 15 patients (40.0%) are alive. The MST of 13 patients after lymph 
node resection was 25.2 months and the OS rates at 1, 2, and 3 years were 76.9%, 52.7%, 
and 26.4%, respectively. Kaplan-Meyer estimate indicated that the OS did not differ 
significantly between patients in group A and group B (P=0.78) (Fig. 2). In addition, neither 
host factors nor tumor factors associated statistically with OS rate. The number of LNM and 
lymph node recurrence after lymhadenectomy were not associated with prognosis. (Table 
III)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 2. 
Kaplan Meier estimate showed that there was no significant difference between OS rate 
of group A and group B (p=0.78).  
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Table II. Treatment courses of 15 patients after lymph node metastasis          
Patient 
number Age Sex 
Synchronous / 
Metachronous 
Treatment before 
lymphadenectomy 
Surgery with 
lymphadenectomy Additional treatment 
Site of 
recurrence 
Survival after
LNR (month) Outcome 
Group A (With Residual Intrahepatic tumors after lymphadenectomy)      
1 60 M Metachronous TACE None PIHP x2 TACE Liver 25.0  Dead (IHTs) 
2 63 M Synchronous None Partial hepatectomy PIHP x2 TACE Liver 34.2  Dead (IHTs) 
3 69 M Metachronous TACE Partial hepatectomy S2 RFA 
Partial hepatectomy 
 RFA  TACE Liver 125.0  Alive 
4 70 M Metachronous TACE Partial hepatectomy None PIHP x1 Liver 7.1  Dead IHTs) 
5 56 M Synchronous None Lt. hemihepatectomy TACE sorafenib 
Liver 
Rectum 25.2  Dead (IHTs) 
6 61 M Synchronous None None PIHP x1 Lateral segmentectomy Liver 43.1  Alive 
7 77 M Synchronous None Lt.hemihepatectomy TACE  RT 
LN 
adrenal grand 16.9  Dead (Brain infarction) 
8 68 M Metachronous Particle radio therapy None TACE Liver 3.3  Alive 
Group B (Complete resection of both LNM and intrahepatic 
tumors)       
9 72 M Metachronous TACE Lt. hemihepatectomy None Liver 3.7  Dead (IHTs) 
10 63 M Metachronous TACE RFA 
Lateral 
segmentectomy TACE Liver 11.5  Dead (IHTs) 
11 72 F Synchronous None Rt hemehepatectomy Lymphadenectomy  Liver LN 43.5  Alive 
12 54 M Metachronous Lt. hemihepatectomyPIHP x2 None Lung resection 
LN 
Lung 12.2  
Dead (Pulmonary 
embolism) 
13 45 M Metachronous RFA Partial hepatectomy Lymphadenectomy  LN 36.8  Dead (Gastric hemorrhage due to LNM)  
14 63 M Synchronous None Lt.hemihepatectomy TACE  sorafenib Liver 22.9  Alive 
15 53 F Metachronous Partial hepatectomy None TACE Liver 1.0  Alive 
LN, lymph node;  LNM, lymph node metastasis;  IHTs, intrahepatic tumors; TACE, transcatheter arterial chemoembilization; PIHP, perctenous isolated hepatic perfusion;  RFA, 
radiofrequency ablation; 
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Variable yes/no MST (month) P  
Host factor    
Age (>65y) 6/9 16.9/25.2 0.92 
Liver status (non LC or LC) 7/8 21.0/34.2 0.94 
Tumor factor    
Larger than 5 cm in diameter 9/6 34.2/18.7 0.15  
Multiple nodules 8/7 25.0/25.2 0.86  
Vascular invasion 9/6 16.9/- 0.11  
LNM factor    
Synchronous LNM 6/9 12.2/34.2 0.15  
Solitary LNM 8/5 25.0/36.8 0.45  
Lymph node recurrence 4/11 26.8/25.2 0.86  
LNM, lymph node metastasis; LC, Liver cirrhosis; MST, median survival time; 
Table III. Univariate analysis associated with overall survival
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
An aggressive surgical treatment is oncologically contraindicated for malignant tumors 
with extensive LNM, because systemic spread of tumor cells is common. Also extended 
resection did not prolong survivals in the majority of patients in such circumstance (4, 18, 20, 
32). Previous studies have shown that LNM of HCC is a poor prognostic factor and surgical 
resection of either intrahepatic tumors or LNM has not gained a wide clinical acceptance to 
date(23). On the other hand, however, several investigators have recently reported that 
long-term survival could be achieved after selective lymphadenectomy, when patients had a 
single LNM. In addition, these studies agreed that the success of locoregional treatment for 
intrahepatic tumors was a key element to prolong survivals in patients with LNM. Thus, it is 
reasonable to assume that selective lymphadenectomy could be a therapeutic option even for 
patients with multiple intrahepatic tumors for which a potent locoregional treatment could 
not be instituted. 
We and others reported that the high efficacy of PIHP in the treatment of patients with 
multiple advanced HCC. In addition, PIHP, when combined with reductive hepatectomy for 
major intrahepatic tumors, it could exert even a stronger impact on multiple residual tumors 
in the liver. This hypothesis has been proven by the results of the dual treatment for patients 
with multiple advanced HCC which previously deemed to have a dismal prognosis. Of note, 
however, complete clearance of both intra- and extrahepatic tumors with surgical resection at 
a time is often difficult especially in patients with the cirrhotic liver. By this reason, 8 
patients solely underwent selective lymphadenectomy at the first stage, and thereafter PIHP 
or other multimodal locoregional treatments such as TACE and RFA were done for 
intrahepatic residual tumors, depending on the number and distribution of hepatic tumors. As 
shown in Fig. 2, it is noteworthy that these 8 patients had an almost equivalent survival curve 
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to those without residual intrahepatic tumors at the time of lymphadenectomy. These results 
most likely support our treatment strategy for patients with multiple advanced HCC and 
LNM.  
Although the number of patients in this pilot study was limited, we speculate that LNM 
from HCC was rather larger in size and smaller in number compared to other gastrointestinal 
malignant diseases. The mean diameter of LNM in this study was 3.6cm and nodes smaller 
than 2cm in diameter were detected in only three patients. On the other hand, the mean 
number of LNM per patient was 1.8 and five or more LNM were observed in only one 
patient. Of interest, gross finding of LNM was expansive in the majority of patients as was 
the dominant macroscopic finding of HCC in the liver. Such growth pattern of LNM from 
HCC may ease surgical resection in views of technical aspect. 
Another to be considered is the mode of extrahepatic recurrence during the course. After 
selective lymphadenectomy, only 4 patients (26.7%) had eventually lymph node recurrence 
and two (13.3%) had distant metastasis other than LNM. This fact implies that LNM of HCC 
does not always indicate untreatable condition of the disease. 
It is well known that the high rate of recurrence even after curative resection in the 
remnant liver is the most prominent feature of HCC. Our data have also shown that the local 
control of intrahepateic tumors was still a major obstacle to prolong survivals in patients with 
LNM. Indeed, intrahepateic recurrence was encountered in 13 of 15 patients. Six of 13 
patients died after intrahepatic recurrence of HCC while death relating to LNM occurred in 
only two patients. Our data indicated that synchronous LNM was not statistically a poor 
prognostic factor. In addition, there was no significant difference between survivals of 
patients with synchronous and metachronous LNM. Other tumor and host factors did not 
differ between these two categories. Although the resectability of LNM was the greatest 
selection bias in our study, these observations strongly indicate that selective 
lymphadectomy can be justified in order to direct our treatment target to the intrahepateic 
tumors. 
PIHP, TACE, and RFA are all locoregional treatment modalities, exerting their effects on 
only for intrahepatic tumors. In this regard surgical resection is the only realistic tool to 
eliminate LNM. Thus, we consider that the most effective therapeutic strategy for advanced 
HCC with LNM is the complete clearance of LNM combined with strategic locoregional 
treatments for intrahepatic tumors. Based on our experience, reductive surgery of major 
intrahepatic tumors and/or selective lymphadenectomy combined with PIHP represents one 
such treatment, and expands the therapeutic targets in patients with multiple intrahepatic 
tumors.  
In conclusion, selective lymphadenectomy and aggressive multimodal and locoregional 
treatments for intrahepatic tumors, as represented by reductive hepatectomy followed by 
PIHP is the treatment of choice in selected HCC patients with multiple intrahepatic lesions 
and LNM. 
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